DDInter351 DDInter899
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Chloramphenicol {u} (Compound) binds {v} (Gene) CYP3A5
Chloramphenicol {u} (Compound) upregulates {v} (Gene) CCNH
Chloramphenicol {u} (Compound) is included by {v} (Pharmacologic Class) Amphenicols
Chloramphenicol {u} (Compound) downregulates {v} (Gene) USP22
Chloramphenicol {u} (Compound) causes {v} (Side Effect) Angioedema
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Chloramphenicol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Chloramphenicol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Elotuzumab
Chloramphenicol {u} may lead to a major life threatening interaction when taken with {v} Flibanserin
Chloramphenicol (Compound) binds CYP3A5 (Gene)
Chloramphenicol (Compound) upregulates CCNH (Gene)
Chloramphenicol (Compound) is included by Amphenicols (Pharmacologic Class)
Chloramphenicol (Compound) downregulates USP22 (Gene)
Chloramphenicol (Compound) causes Angioedema (Side Effect)
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Donepezil
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Chloramphenicol may lead to a major life threatening interaction when taken with Flibanserin